Drug intelligence / Profile preview

Vybrin

Development stage
Unknown
Lead developer
Allergan
Modality
Recombinant Proteins and Enzymes
Administration
Topical
01

Overview

Vybrin is a fibrin sealant designed for use as a surgical adhesive and hemostatic agent. It is a biological product typically composed of two primary components: human fibrinogen and human thrombin. When these components are mixed during application, they mimic the final stage of the natural blood coagulation cascade, converting fibrinogen into a fibrin clot. This fibrin matrix adheres to the wound surface, providing a physical barrier that promotes hemostasis and tissue sealing. Vybrin was developed to assist in controlling bleeding in surgical procedures where conventional techniques, such as sutures or cautery, are ineffective or impractical. It has been utilized in various surgical settings, including cardiovascular and general surgery, to prevent fluid leaks and support wound healing.

Brand names
Vybrin
Other names
Vybrin Fibrin Sealant
02

Targets

FXIIIa (Coagulation factor XIII A subunit)PLG (Plasminogen)F2 (Thrombin)F5 (Coagulation Factor V)F8 (Coagulation Factor VIIIa)F11 (Coagulation Factor XI)Coagulation Factor XIIIF2R (Protease-activated receptor 1)PAR2 (Protease-activated receptor 2)PAR4 (Protease-activated receptor 4)

Beyond the preview

Go deeper on Vybrin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vybrin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call